• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
Conclusions -Serial assessment of hsTnI revealed a substantial proportion of patients with T2DM without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes based on risk. Clinical Trial Registration -https://clinicaltrials.gov Identifier: NCT00968708. PMID: 28246236 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA Tags: Circulation Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV) events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little to no impact on reducing CV risk, especially in patients with a long duration of T2D and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic medications that increase urinary glucose excretion, thus improving glycaemic control independent of insulin. The recently published CV outc...
Source: European Heart Journal - November 16, 2016 Category: Cardiology Authors: Marx, N., McGuire, D. K. Tags: Clinical update Source Type: research

Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
Conclusions In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent.
Source: Heart - September 12, 2016 Category: Cardiology Authors: Anyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., Idris, I. Tags: Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology, Diabetes, Metabolic disorders Healthcare delivery, economics and global health Source Type: research

Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (From the Treating to New Targets (TNT) and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trials)
The goal of this analysis was to evaluate the ability of insulin resistance, identified by the presence of prediabetes mellitus (PreDM) combined with either an elevated triglyceride (TG>1.7mmol/L) or body mass index (BMI> 27.0 kg/m2), to identify increased risk of statin-associated type 2 diabetes mellitus (T2DM). Consequently, a retrospective analysis of data from non-diabetic individuals in the TNT and SPARCL randomized controlled trials was performed, subdividing participants into 4 experimental groups: 1) normal fasting glucose (NFG) and TG ≤ 1.7 mmol/L (42%); 2) NFG and TG> 1.7 mmol/L (22%); 3) PreDM and TG ≤ 1.7 ...
Source: The American Journal of Cardiology - August 11, 2016 Category: Cardiology Authors: Payal Kohli, Joshua W. Knowles, Ashish Sarraju, David D. Waters, Gerald Reaven Source Type: research

Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1
Publication date: September 2016 Source:American Heart Journal, Volume 179 Author(s): Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown Frandsen, Rasmus Rabøl, John B. Buse DEVOTE was designed to evaluate the cardiovascular safety of insulin degludec (IDeg) vs insulin glargine U100 (IGlar) in patients with T2D at high risk of cardiovascular events. DEVOTE is a phase 3b, multicenter, international, randomized, double-blind, active comparator-controlled trial, designed as an event-driven t...
Source: American Heart Journal - July 30, 2016 Category: Cardiology Source Type: research

Cardiovascular safety of insulin degludec versus insulin glargine in patients at high risk of cardiovascular events: Design of the DEVOTE Cardiovascular Outcomes Trial (DEVOTE 1)
Publication date: Available online 18 June 2016 Source:American Heart Journal Author(s): Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown Frandsen, Rasmus Rabøl, John B. Buse The Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was designed to evaluate the cardiovascular safety of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes at high risk of c...
Source: American Heart Journal - June 17, 2016 Category: Cardiology Source Type: research

Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes
Abstract Sedentary life style and high calorie dietary habits are prominent leading cause of metabolic syndrome in modern world. Obesity plays a central role in occurrence of various diseases like hyperinsulinemia, hyperglycemia and hyperlipidemia, which lead to insulin resistance and metabolic derangements like cardiovascular diseases (CVDs) mediated by oxidative stress. The mortality rate due to CVDs is on the rise in developing countries. Insulin resistance (IR) leads to micro or macro angiopathy, peripheral arterial dysfunction, hampered blood flow, hypertension, as well as the cardiomyocyte and the endothelia...
Source: Heart Failure Reviews - November 5, 2015 Category: Cardiology Source Type: research

Abstract P636: Sex Differences in Cardioprotective AT2R Expression in Diabetic Rats and Its Correlation with Myocardial Damage Session Title: Diabetes, Nutrition and Obesity/Insulin and Metabolic Syndrome
Diabetes mellitus (DM) is an independent risk factor for cardiovascular disease (CVD). Healthy, young women are protected from CVD, while diabetic women are more susceptible to CVD compared to age-matched diabetic men and non-diabetic women. Underlying mechanisms for this sex difference in CVD are not fully elucidated. The angiotensin II type 2 receptor (AT2R) is a member of the protective, vasodilative arm of the renin angiotensin system. The Agtr2 gene that codes for AT2R is X-linked, and increased Agtr2 expression is reported in female vasculature of rodent models. We hypothesized that a sex difference might exist in DM...
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Lum-Naihe, K., Mahmood, A., Bajwa, J., Emter, C. A., Pulakat, L. Tags: Session Title: Diabetes, Nutrition and Obesity/Insulin and Metabolic Syndrome Source Type: research

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research

Plasma Levels of Soluble IL-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan.
CONCLUSIONS: These results support a role for sIL-2Rα in atherosclerosis and provide evidence for multiple-associated single-nucleotide polymorphisms at chromosome 10p15-14. PMID: 26293465 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 20, 2015 Category: Cardiology Authors: Durda P, Sabourin J, Lange EM, Nalls MA, Mychaleckyj JC, Jenny NS, Li J, Walston J, Harris TB, Psaty BM, Valdar W, Liu Y, Cushman M, Reiner AP, Tracy RP, Lange LA Tags: Arterioscler Thromb Vasc Biol Source Type: research

Lifestyle Choices Fuel Epidemics of Diabetes and Cardiovascular Disease among Asian Indians
Within the next 15 years, India is projected to overtake China as the world’s most populous nation. Due to the rapid pace of urbanization and modernization fueling population growth, in conjunction with a genetic predisposition to insulin resistance, India is suffering a rising epidemic of non-communicable diseases (NCDs), including coronary artery disease (CAD), type 2 diabetes mellitus (T2DM), and stroke. In addition to the genetic predisposition, major negative lifestyle factors are contributing to the alarming outbreak of cardiovascular disease (CVD) among the Asian Indian population; these factors include:1) a diet ...
Source: Progress in Cardiovascular Diseases - August 12, 2015 Category: Cardiology Authors: Evan L. O’Keefe, James J. DiNicolantonio, Harshal Patil, John H. Helzberg, Carl J. Lavie Source Type: research

High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry Coronary Interventions
Conclusions— The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
Source: Circulation: Cardiovascular Interventions - May 29, 2015 Category: Cardiology Authors: Ritsinger, V., Saleh, N., Lagerqvist, B., Norhammar, A. Tags: Type 2 diabetes, Catheter-based coronary interventions: stents Source Type: research

Adiponectin, type 2 diabetes and cardiovascular risk
Conclusions In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.
Source: European Journal of Preventive Cardiology - February 10, 2015 Category: Cardiology Authors: Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., Mogelvang, R. Tags: Original scientific paper Source Type: research

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM). Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral ...
Source: Cardiovascular Diabetology - January 24, 2015 Category: Cardiology Authors: Sanjoy PaulKerenaftali KleinDavid MaggsJennie Best Source Type: research

Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control
Conclusions: In patients with type 2 diabetes, ADMA might be an independent risk factor for long-term adverse cardiovascular events. However, ADMA was not correlated with serum HbA1c level, and in diabetic patients with HbA1c ?6.5%, elevated ADMA level was no longer associated with increased risk of long-term prognosis. Our findings suggested that the prognosis predictive value of ADMA in type 2 diabetes might be modified by the glycemic control.
Source: Cardiovascular Diabetology - December 3, 2014 Category: Cardiology Authors: Chiao-Po HsuPai-Feng HsuMing-Yi ChungShing-Jong LinTse-Min Lu Source Type: research

Pages: 1  2  3  4